Persistence of newer anti-obesity medications in a real-world setting

Evaluate real-world data on persistence with anti-obesity medications (AOMs) and explore associated patient factors. Truven Health MarketScan® data were analyzed to evaluate utilization of AOMs approved for long-term use between 4/2015 and 3/2016. Kaplan-Meier survival analyses were used to evaluate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes research and clinical practice 2018-09, Vol.143, p.348-356
Hauptverfasser:	Ganguly, Rahul, Tian, Ye, Kong, Sheldon X., Hersloev, Malene, Hobbs, Todd, Smolarz, B. Gabriel, Ramasamy, Abhilasha, Haase, Christiane Lundegaard, Weng, Wayne
Format:	Artikel
Sprache:	eng
Schlagworte:	Adherence Anti-obesity medications AOM Liraglutide Long-term Obesity Persistence Pharmacotherapy Real-world Retrospective
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	356
container_issue
container_start_page	348
container_title	Diabetes research and clinical practice
container_volume	143
creator	Ganguly, Rahul Tian, Ye Kong, Sheldon X. Hersloev, Malene Hobbs, Todd Smolarz, B. Gabriel Ramasamy, Abhilasha Haase, Christiane Lundegaard Weng, Wayne
description	Evaluate real-world data on persistence with anti-obesity medications (AOMs) and explore associated patient factors. Truven Health MarketScan® data were analyzed to evaluate utilization of AOMs approved for long-term use between 4/2015 and 3/2016. Kaplan-Meier survival analyses were used to evaluate treatment persistence. A multivariate analysis was performed to identify associations between persistence and relevant factors. In total, 26,522 adult patients were identified as newly prescribed naltrexone/bupropion (44.0%, mean age 47.1, 80.5% female), lorcaserin (24.8%, 48.5, 79.3%), phentermine/topiramate extended release (15.8%, 46.7, 82.2%) or liraglutide 3.0 mg (15.4%, 46.9, 72.4%). At 6 months, 41.8% of patients were still on liraglutide 3.0 mg, compared to 15.9% lorcaserin (p
doi_str_mv	10.1016/j.diabres.2018.07.017
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2070803806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168822718309422</els_id><sourcerecordid>2070803806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-44628cdc405f374a02d6a31645c6acd92b9ef18a529ca75fdf6b973711ed42623</originalsourceid><addsrcrecordid>eNqFkMtOwzAURC0EoqXwCSAv2ST4kdjOCiFUHlIlWMDacuwb5CpNwHZB_XtcWtiyurOYuaM5CJ1TUlJCxdWydN60AWLJCFUlkSWh8gBNqZKsUIzJQzTNPvWjJ-gkxiUhRPCqPkYTnmXTcDlF82cI0ccEgwU8dniALwjYDMkXYwvRpw1egfPWJD8OEfsBGxzA9MXXGHqHI6Tkh7dTdNSZPsLZ_s7Q69385fahWDzdP97eLArLRZ2KqhJMWWcrUndcVoYwJwynoqqtMNY1rG2go8rUrLFG1p3rRNtILikFVzHB-Axd7v6-h_FjDTHplY8W-t4MMK6jZkQSRbjKO2eo3lltGGMM0On34FcmbDQlektQL_WeoN4S1ETqTDDnLvYV6zYv_0v9IsuG650B8tBPD0FH67f4nA9gk3aj_6fiG1LXhDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2070803806</pqid></control><display><type>article</type><title>Persistence of newer anti-obesity medications in a real-world setting</title><source>Elsevier ScienceDirect Journals</source><creator>Ganguly, Rahul ; Tian, Ye ; Kong, Sheldon X. ; Hersloev, Malene ; Hobbs, Todd ; Smolarz, B. Gabriel ; Ramasamy, Abhilasha ; Haase, Christiane Lundegaard ; Weng, Wayne</creator><creatorcontrib>Ganguly, Rahul ; Tian, Ye ; Kong, Sheldon X. ; Hersloev, Malene ; Hobbs, Todd ; Smolarz, B. Gabriel ; Ramasamy, Abhilasha ; Haase, Christiane Lundegaard ; Weng, Wayne</creatorcontrib><description><![CDATA[Evaluate real-world data on persistence with anti-obesity medications (AOMs) and explore associated patient factors. Truven Health MarketScan® data were analyzed to evaluate utilization of AOMs approved for long-term use between 4/2015 and 3/2016. Kaplan-Meier survival analyses were used to evaluate treatment persistence. A multivariate analysis was performed to identify associations between persistence and relevant factors. In total, 26,522 adult patients were identified as newly prescribed naltrexone/bupropion (44.0%, mean age 47.1, 80.5% female), lorcaserin (24.8%, 48.5, 79.3%), phentermine/topiramate extended release (15.8%, 46.7, 82.2%) or liraglutide 3.0 mg (15.4%, 46.9, 72.4%). At 6 months, 41.8% of patients were still on liraglutide 3.0 mg, compared to 15.9% lorcaserin (p < 0.001), 18.1% naltrexone/bupropion (p < 0.001), and 27.3% phentermine/topiramate (p < 0.001). After adjusting for baseline factors, patients on liraglutide 3.0 mg had significantly lower risk of discontinuation compared to those on lorcaserin (HR = 0.46, p < 0.0001), naltrexone/bupropion (HR = 0.48, p < 0.0001), and phentermine/topiramate (HR = 0.64, p < 0.0001) over the course of follow-up (mean follow-up duration, 342–427 days). Older age, male gender, having hyperlipidemia, and no prior phentermine use were associated with higher persistence. Over 95% of study patients had commercial insurance. In a real-world setting, patients on liraglutide 3.0 mg had the highest persistence rate of the four AOMs studied.]]></description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2018.07.017</identifier><identifier>PMID: 30009937</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Adherence ; Anti-obesity medications ; AOM ; Liraglutide ; Long-term ; Obesity ; Persistence ; Pharmacotherapy ; Real-world ; Retrospective</subject><ispartof>Diabetes research and clinical practice, 2018-09, Vol.143, p.348-356</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-44628cdc405f374a02d6a31645c6acd92b9ef18a529ca75fdf6b973711ed42623</citedby><cites>FETCH-LOGICAL-c365t-44628cdc405f374a02d6a31645c6acd92b9ef18a529ca75fdf6b973711ed42623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168822718309422$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30009937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ganguly, Rahul</creatorcontrib><creatorcontrib>Tian, Ye</creatorcontrib><creatorcontrib>Kong, Sheldon X.</creatorcontrib><creatorcontrib>Hersloev, Malene</creatorcontrib><creatorcontrib>Hobbs, Todd</creatorcontrib><creatorcontrib>Smolarz, B. Gabriel</creatorcontrib><creatorcontrib>Ramasamy, Abhilasha</creatorcontrib><creatorcontrib>Haase, Christiane Lundegaard</creatorcontrib><creatorcontrib>Weng, Wayne</creatorcontrib><title>Persistence of newer anti-obesity medications in a real-world setting</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description><![CDATA[Evaluate real-world data on persistence with anti-obesity medications (AOMs) and explore associated patient factors. Truven Health MarketScan® data were analyzed to evaluate utilization of AOMs approved for long-term use between 4/2015 and 3/2016. Kaplan-Meier survival analyses were used to evaluate treatment persistence. A multivariate analysis was performed to identify associations between persistence and relevant factors. In total, 26,522 adult patients were identified as newly prescribed naltrexone/bupropion (44.0%, mean age 47.1, 80.5% female), lorcaserin (24.8%, 48.5, 79.3%), phentermine/topiramate extended release (15.8%, 46.7, 82.2%) or liraglutide 3.0 mg (15.4%, 46.9, 72.4%). At 6 months, 41.8% of patients were still on liraglutide 3.0 mg, compared to 15.9% lorcaserin (p < 0.001), 18.1% naltrexone/bupropion (p < 0.001), and 27.3% phentermine/topiramate (p < 0.001). After adjusting for baseline factors, patients on liraglutide 3.0 mg had significantly lower risk of discontinuation compared to those on lorcaserin (HR = 0.46, p < 0.0001), naltrexone/bupropion (HR = 0.48, p < 0.0001), and phentermine/topiramate (HR = 0.64, p < 0.0001) over the course of follow-up (mean follow-up duration, 342–427 days). Older age, male gender, having hyperlipidemia, and no prior phentermine use were associated with higher persistence. Over 95% of study patients had commercial insurance. In a real-world setting, patients on liraglutide 3.0 mg had the highest persistence rate of the four AOMs studied.]]></description><subject>Adherence</subject><subject>Anti-obesity medications</subject><subject>AOM</subject><subject>Liraglutide</subject><subject>Long-term</subject><subject>Obesity</subject><subject>Persistence</subject><subject>Pharmacotherapy</subject><subject>Real-world</subject><subject>Retrospective</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOwzAURC0EoqXwCSAv2ST4kdjOCiFUHlIlWMDacuwb5CpNwHZB_XtcWtiyurOYuaM5CJ1TUlJCxdWydN60AWLJCFUlkSWh8gBNqZKsUIzJQzTNPvWjJ-gkxiUhRPCqPkYTnmXTcDlF82cI0ccEgwU8dniALwjYDMkXYwvRpw1egfPWJD8OEfsBGxzA9MXXGHqHI6Tkh7dTdNSZPsLZ_s7Q69385fahWDzdP97eLArLRZ2KqhJMWWcrUndcVoYwJwynoqqtMNY1rG2go8rUrLFG1p3rRNtILikFVzHB-Axd7v6-h_FjDTHplY8W-t4MMK6jZkQSRbjKO2eo3lltGGMM0On34FcmbDQlektQL_WeoN4S1ETqTDDnLvYV6zYv_0v9IsuG650B8tBPD0FH67f4nA9gk3aj_6fiG1LXhDQ</recordid><startdate>20180901</startdate><enddate>20180901</enddate><creator>Ganguly, Rahul</creator><creator>Tian, Ye</creator><creator>Kong, Sheldon X.</creator><creator>Hersloev, Malene</creator><creator>Hobbs, Todd</creator><creator>Smolarz, B. Gabriel</creator><creator>Ramasamy, Abhilasha</creator><creator>Haase, Christiane Lundegaard</creator><creator>Weng, Wayne</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180901</creationdate><title>Persistence of newer anti-obesity medications in a real-world setting</title><author>Ganguly, Rahul ; Tian, Ye ; Kong, Sheldon X. ; Hersloev, Malene ; Hobbs, Todd ; Smolarz, B. Gabriel ; Ramasamy, Abhilasha ; Haase, Christiane Lundegaard ; Weng, Wayne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-44628cdc405f374a02d6a31645c6acd92b9ef18a529ca75fdf6b973711ed42623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adherence</topic><topic>Anti-obesity medications</topic><topic>AOM</topic><topic>Liraglutide</topic><topic>Long-term</topic><topic>Obesity</topic><topic>Persistence</topic><topic>Pharmacotherapy</topic><topic>Real-world</topic><topic>Retrospective</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ganguly, Rahul</creatorcontrib><creatorcontrib>Tian, Ye</creatorcontrib><creatorcontrib>Kong, Sheldon X.</creatorcontrib><creatorcontrib>Hersloev, Malene</creatorcontrib><creatorcontrib>Hobbs, Todd</creatorcontrib><creatorcontrib>Smolarz, B. Gabriel</creatorcontrib><creatorcontrib>Ramasamy, Abhilasha</creatorcontrib><creatorcontrib>Haase, Christiane Lundegaard</creatorcontrib><creatorcontrib>Weng, Wayne</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ganguly, Rahul</au><au>Tian, Ye</au><au>Kong, Sheldon X.</au><au>Hersloev, Malene</au><au>Hobbs, Todd</au><au>Smolarz, B. Gabriel</au><au>Ramasamy, Abhilasha</au><au>Haase, Christiane Lundegaard</au><au>Weng, Wayne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Persistence of newer anti-obesity medications in a real-world setting</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2018-09-01</date><risdate>2018</risdate><volume>143</volume><spage>348</spage><epage>356</epage><pages>348-356</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><abstract><![CDATA[Evaluate real-world data on persistence with anti-obesity medications (AOMs) and explore associated patient factors. Truven Health MarketScan® data were analyzed to evaluate utilization of AOMs approved for long-term use between 4/2015 and 3/2016. Kaplan-Meier survival analyses were used to evaluate treatment persistence. A multivariate analysis was performed to identify associations between persistence and relevant factors. In total, 26,522 adult patients were identified as newly prescribed naltrexone/bupropion (44.0%, mean age 47.1, 80.5% female), lorcaserin (24.8%, 48.5, 79.3%), phentermine/topiramate extended release (15.8%, 46.7, 82.2%) or liraglutide 3.0 mg (15.4%, 46.9, 72.4%). At 6 months, 41.8% of patients were still on liraglutide 3.0 mg, compared to 15.9% lorcaserin (p < 0.001), 18.1% naltrexone/bupropion (p < 0.001), and 27.3% phentermine/topiramate (p < 0.001). After adjusting for baseline factors, patients on liraglutide 3.0 mg had significantly lower risk of discontinuation compared to those on lorcaserin (HR = 0.46, p < 0.0001), naltrexone/bupropion (HR = 0.48, p < 0.0001), and phentermine/topiramate (HR = 0.64, p < 0.0001) over the course of follow-up (mean follow-up duration, 342–427 days). Older age, male gender, having hyperlipidemia, and no prior phentermine use were associated with higher persistence. Over 95% of study patients had commercial insurance. In a real-world setting, patients on liraglutide 3.0 mg had the highest persistence rate of the four AOMs studied.]]></abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>30009937</pmid><doi>10.1016/j.diabres.2018.07.017</doi><tpages>9</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0168-8227
ispartof	Diabetes research and clinical practice, 2018-09, Vol.143, p.348-356
issn	0168-8227 1872-8227
language	eng
recordid	cdi_proquest_miscellaneous_2070803806
source	Elsevier ScienceDirect Journals
subjects	Adherence Anti-obesity medications AOM Liraglutide Long-term Obesity Persistence Pharmacotherapy Real-world Retrospective
title	Persistence of newer anti-obesity medications in a real-world setting
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T03%3A09%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Persistence%20of%20newer%20anti-obesity%20medications%20in%20a%20real-world%20setting&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Ganguly,%20Rahul&rft.date=2018-09-01&rft.volume=143&rft.spage=348&rft.epage=356&rft.pages=348-356&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2018.07.017&rft_dat=%3Cproquest_cross%3E2070803806%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2070803806&rft_id=info:pmid/30009937&rft_els_id=S0168822718309422&rfr_iscdi=true